Travere Therapeutics (TVTX)
(Real Time Quote from BATS)
$16.66 USD
+0.70 (4.39%)
Updated Aug 5, 2025 03:00 PM ET
4-Sell of 5 4
D Value D Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TVTX 16.66 +0.70(4.39%)
Will TVTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TVTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TVTX
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Compared to Estimates, Travere (TVTX) Q1 Earnings: A Look at Key Metrics
TVTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Travere Therapeutics (TVTX) Reports Q1 Loss, Tops Revenue Estimates
Vertex Pharmaceuticals (VRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Novavax (NVAX) Soars 11.4%: Is Further Upside Left in the Stock?
Other News for TVTX
Earnings To Watch: Travere Therapeutics Inc (TVTX) Reports Q2 2025 Result
Travere Therapeutics to Report Second Quarter 2025 Financial Results | TVTX Stock News
Behind The Volatility Of Vera Therapeutics
Travere Therapeutics Inc (TVTX) Announces Inducement Equity Grants to New Employees | TVTX ...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | TVTX ...